We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Sunshine Guojian

News List

Which Will Market the First Chinese-produced Trastuzumab Biosimilar: Sunshine Guojian or Henlius? PharmaSources/Dopine
June 15, 2020
HER2-positive breast cancer has a high degree of malignancy and fast progression. Trastuzumab is the standard first-line regimen for adjuvant, neoadjuvant and metastatic cancer treatment of HER2-positive breast cancer.
Sunshine Guojian Selects Verseau's VSIG4-targeted Antibody as the Second Partnered Macrophage Checkpoint Modulator in Immuno-Oncology Collaboration prnasia
December 15, 2020
3SBio Inc.'s subsidiary, Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd. and Verseau Therapeutics, Inc. announced the selection of a monoclonal antibody targeting VSIG4, as a licensed program under their partnership agreement focused on the ...